Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZPL-3893787-18 in Moderate to Severe Plaque Psoriasis
2015-003812-19Phase 2Completed
- Sponsor
- Ziarco Pharma Ltd
- Start
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in plaque psoriasis comparing ZPL-3893787-18 30 mg once daily with Placebo once daily (2 arms). Primary endpoint: Primary: Percentage change from baseline in PASI score. Started Oct 2015; status: completed.
02
Drugs
adriforant
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2015-003812-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003812-19.